Effects of Rosemary (Rosmarinus officinalis) Leaves Powder And Weight Reducing Diet on Hs-CRP, MDA, TAC, Blood Pressure, Anthropometric measurement, Quality of life, Sleep and Appetite in Patients with Non-Alcoholic Fatty Liver Disease

Phase 2

Recruiting

• Conditions: onalcoholic fatty liver disease.; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20120415009472N19
• Lead Sponsor: Vice-chancellor for research Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 5 November 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

Desire to participate in studying and signing consent
Evidence of hepatic steatosis in liver ultrasonography (grade 1 to 3 fatty liver)
Increased liver enzymes than normal (AST> 38 and ALT> 40 for men and AST> 31 and ALT> 33 for women)
BMI in the range of 25-40 kg / m2
aged between 20 and 65 years

Exclusion Criteria

Unwillingness to participate in the study
Secondary conditions that lead to hepatic steatosis, including: alcohol consumption, hereditary disorders affecting liver status (hemochromatosis and Wilson's disease), and known autoimmune disease
Other chronic and acute liver diseases and disorders such as hepatitis, cirrhosis, celiac disease, diabetes, thyroid disorders, cardiovascular, renal, pulmonary and inflammatory diseases (rheumatism)
History of taking hepatotoxic drugs (methotrexate, amiodarone, tamoxifen, nifedipine, corticosteroids, valproate and antiviral drugs) as well as anticoagulants such as aspirin
Use of any nutritional supplement in the past two months
Use of weight-loss drugs over the past two months
Having a severe weight loss diet (more than 10% weight loss) over the past three months
smoking
Pregnancy or lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Malondialdehyde. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;Total Antioxidant Capacity. Timepoint: Before intervention and 8 weak after intervention. Method of measurement: Colorimetric method.;High sensitivity C-reactive protein. Timepoint: Before intervention and 12 weak after intervention. Method of measurement: Turbidometric method.